Back to search results
NCT07145346

Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures

Enrolling by Invitation
PHASE4Ages 18+InterventionalTreatment
University of California, Irvine
~80 participants
Updated 2025-12-08 on ClinicalTrials.gov
What's tested:Suzetrigine (SUZ)Placebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluation of Pain
Measured over Through study completion of index hospitalization (up to 2 years)
+1 more outcome measured

Conditions

Rib Fractures

Explore related trials

Rib Fracture

Where it's being run

1 sites across 1 states
California1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\> 18 years old
Blunt trauma patients
\> 3 rib fractures
Able to tolerate oral intake

Exclusion

\< 17 years old
Pregnant
Prisoners
History of adverse reaction to suzetrigine
Current strong CYP3A inhibitor medication use
Current strong or moderate CYP3A inducer
Strong Inducers: apalutamide, carbamazepine, encorafenib, enzalutamide, fosphenytoin, lumacaftor and ivacaftor, mitotane, phenytoin, rifampin
Moderate Inducers: bexarotene (Systemic), bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, estradiol, and norethindrone, eslicarbazepine, etravirine, fexinidazole, lorlatinib, mitapivat, modafinil, nafcillin, pacritinib, pexidartinib, phenobarbital, primidone, repotrectinib, rifabutin, rifapentine, sotorasib, St John's Wort
Cirrhosis
GCS \< 14
Rhabdomyolysis (CPK \> 5,000 U/L)
Chronic opioid use (\>30mg OME/day)
Known or suspected active infection with human immunodeficiency virus or hepatitis B or C viruses

What this trial measures

  • Evaluation of PainThrough study completion of index hospitalization (up to 2 years)

    Pain will be measured on a numerical pain scale from 0 (no pain) to 10 (most pain). Higher pain scores equate to worse outcomes.

  • Use of morphine and morphine equivalentsThrough study completion of index hospitalization (up to 2 years)

    Oral morphine equivalents (OME) - A study team member will do a chart review and collect morphine used by the patients.